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arthritis (RA), ankylosing spondylitis (AS), and psoriasis on work
productivity, to calculate the productivity costs (PC), and to map out
factors that inﬂuence (functional status and disease activity) work
productivity. Methods: The Work Productivity and Activity Impair-
ment questionnaire was used to evaluate productivity losses of
patients with RA (n ¼ 77), AS (n ¼ 230), and psoriasis (n ¼ 93).
Demographic data, patient-reported outcomes (PROs) (Health Assess-
ment Questionnaire [HAQ] and Bath Ankylosing Spondylitis Disease
Activity Index [BASDAI]), and clinical parameters (Disease Activity
Score in 28 joints [DAS28], body surface area [BSA], and Psoriasis Area
and Severity Index [PASI]) were collected. The correlations among
PROs, clinical parameters, and overall productivity loss were exam-
ined, and multiple regression models were used to examine relation-
ships among parameters and productivity loss. PC were calculated
using the friction cost approach. Results: Mean patient age and
disease duration were 47.1 and 15.7 years, respectively. The mean
HAQ and DAS28 in patients with RA were 1.22 and 5.6, respectively.
The mean BASDAI score in patients with AS was 4.43. The mean BSAee front matter Copyright & 2014, International S
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ech Republic.and PASI score in patients with psoriasis were 21.1% and 12.9,
respectively. The percentage of patients with psoriatic arthritis (in those
with psoriasis) was 24.7%. We did not ﬁnd signiﬁcant differences in Work
Productivity and Activity Impairment domains among various diagnoses.
Patients with AS, RA, and psoriasis reported overall work productivity
losses of 40.9%, 42.9%, and 42.8%, respectively. Daily activity impairments
were approximately 50.0%. Overall work productivity loss strongly
correlated with PROs, whereas correlations with clinical parameters were
weak. The HAQ and BASDAI were identiﬁed as major predictors of
productivity impairment. Conclusions: The greatest loss in productivity
was in those with psoriatic arthritis; however, it was not signiﬁcant. In
contrast to clinical parameters (DAS28, BSA, and PASI score), PROs (HAQ
and BASDAI score) signiﬁcantly inﬂuence loss of productivity. The
average annual lost PC per patient was estimated to be €2000.
Keywords: ankylosing spondylitis, productivity costs, psoriasis,
psoriatic arthritis, rheumatoid arthritis, work productivity, WPAI.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psor-
iasis are chronic diseases leading to progressive disability, with
signiﬁcant costs arising not only to the health care system.
Hence, the performance of health economic studies from the
health care system perspective leads to substantial underestima-
tion of total disease burden [1,2].
Patients suffer from decreased quality of life related to health
problems; in addition, there are work restrictions and lost work
productivity resulting from these diseases, with lost productivity
being related to diminished participation in the labor market [3].
Reduced work opportunities affect both the national economy
and personal ﬁnances and contribute overall to reduced quality
of life [4].During the illness, patients can move among different health
states; there can be periods of normal productivity, presenteeism,
the state of being at work but working at reduced productivity,
also referred to as “at-work productivity loss” or “at-work dis-
ability”, interspersed with reduced productivity associated with
increased temporary absenteeism, as well as periods of chronic
or permanent absenteeism [5,6].
In cases of RA, 20% to 30% of the patients have been reported
to have become totally disabled in the ﬁrst 2 to 3 years after the
disease was diagnosed [7].
Kobelt et al. [8] states that the overall percentage of patients
who must leave their jobs is 20% to 50%, depending on the sample
of patients and the country where the study was conducted.
The prevalence of these chronic conditions (i.e., RA, AS, and
psoriasis) ranges from 0.1% to 1.0% of the population [9,10]. Theociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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affect the entire productive life of the individual [11]. This is why
these conditions generate not only health costs but also signiﬁ-
cant costs to patients, employers, and society as a whole [12].
With the increasing loss of productivity (due to physical
impairment), signiﬁcant costs associated with lost productivity
are generated. From the societal and patient perspective, these
costs are referred to as “productivity costs” (PC) and “productivity
loss,” respectively. These costs represent 40% to 80% of the total
societal cost attributed to these diseases (RA, AS, psoriasis) [13].
Another important part of the costs is social pensions and
various allowances based on the degree of dependence [14],
which is indirect costs that the government bear and do not
represent the productivity costs from the societal perspective
[15].
In general, there is no discussion that the burden of rheumatic
diseases and psoriasis on the society is substantial. There are
several methods of measurement and valuation of the produc-
tivity impairment and productivity costs. Based on different
approaches of quantiﬁcation of productivity losses, the overall
calculated impact/economic burden can differ signiﬁcantly
[16,17]. It should also be noted that there are differences in
guidelines across countries on how to implement productivity
losses and costs into decision making [17].
Several instruments/questionnaires are used for the measure-
ment of productivity and disability in rheumatic diseases and
psoriasis. These instruments have proved their reliability, val-
idity, and responsiveness in various diseases. The most fre-
quently used instruments are Rheumatoid Arthritis Speciﬁc
Work Productivity Survey, Workplace Activity Limitations Scale,
Work Instability Scale for Rheumatoid Arthritis, Work Limitations
Questionnaire, and Work Productivity and Activity Impairment
(WPAI) questionnaire [5,18]. The development of the “ideal” tool
for the valuation of productivity losses, however, is still a subject
of research [19–21].
Two main approaches are used for calculating the costs
associated with reduced or lost productivity. The ﬁrst approach
is the human capital approach, which includes the value of any
potentially lost productivity. Productivity loss is then calculated
or monetized as all of the expected or potential loss of proﬁt
because of an illness, disability, or a prematurely deceased
patient. An essential precondition for the application of this
human capital approach method is the “absolute loss of produc-
tivity” and the impossibility of its replacement; therefore, a fully
utilized labor force is assumed (i.e., zero unemployment) [8,22].
The second approach used for calculating productivity costs is
the friction cost approach (FCA). This approach assumes that
those with reduced or lost productivity will be replaced by other
workers. In this scenario, productivity loss is calculated as the
maximum period of time needed to restore full productivity of
the position concerned. This period of time is called the “friction
period”; after expiration of the friction period, the cost to society
is assumed to be zero. The friction period should also include the
new employee’s training period [8,23].Methods
The study was carried out using cross-sectional data collection
among randomly selected patients from a patient organization
(AS), specialized centers for the treatment of skin diseases (four
centers for psoriasis), and specialized centers for the treatment of
rheumatic diseases (three centers for RA). Data collection was
performed through self-reporting questionnaires returned by
regular mail for patients with AS (65% recoverability) and by
direct physician-administered questionnaires for patients with
RA and psoriasis.Structure and scope of the data were represented by the WPAI
questionnaire in patients with relevant diagnoses [24], a Health
Assessment Questionnaire (HAQ) [25], and the Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI) [26]. In addition, the
Disease Activity Score in 28 joints (DAS28) in patients with RA,
body surface area (BSA), and Psoriasis Area and Severity Index
(PASI) in patients with psoriasis were collected.
Demographic data (age, sex, work status, educational level)
and the year of diagnosis were also collected. Patients were
eligible for the study if they were in their productive years.
Hence, old-age pensioners (retirement pension patients), stu-
dents, and women on maternity leave were excluded from
the study.
The WPAI:Speciﬁc Health Problem questionnaire is a variation
of a speciﬁc questionnaire developed to measure the impact of
speciﬁc diseases on work productivity. The questionnaire has
demonstrated validity, reliability, and sufﬁcient predictive value
to measure the impact of the disease with regard to absenteeism,
presenteeism, and overall productivity impairment in such a way
that it could be monetized [27–29]. In general, the WPAI ques-
tionnaire is a quantitative tool used for measuring reduced
productivity at work and during leisure activities (i.e., typical
activities that a person performs on a regular basis, such as
household activities, shopping, childcare, and exercising). Four
scores, expressed as percentage deterioration, are obtained from
the WPAI questionnaire. Higher percentage scores are worse in
terms of absenteeism, presenteeism, overall productivity, and
leisure activity impairment relative to lower scores.
The HAQ is used to monitor functional abilities of patients
with RA. It is intended to reﬂect the impact of the disease on daily
life. It contains 20 questions regarding ability to perform activities
in eight areas (dressing and grooming, rising, eating, walking,
hygiene, reach, grip, and activities). The ﬁnal score ranges from 0
to 3, where 0 indicates no functional impairment and 3 indicates
the worst impairment. For some analysis, we divided patients
with RA according to their HAQ score into ﬁve categories [30]. The
BASDAI questionnaire focuses on the subjective assessment of
disease activity (or disease status) in patients with AS. It uses six
questions. Using a visual analogue scale, patients record their
degree of fatigue, spinal pain, joint pain/swelling, areas of
localized tenderness, and severity and duration of morning stiff-
ness. The total score can range from 0 to 10, with higher values
indicating greater disease activity or limitations. A score higher
than 4 indicates very active disease [31].
DAS28 was used for evaluation activity in patients with RA
and psoriatic arthritis. DAS28 is derived by assessing the number
of swollen and tender joints, sedimentation, and global assess-
ment of the patient [32,33].
The PASI score and BSA were used to evaluate the severity of
skin changes (size of the affected BSA) of patients with psoriasis.
The PASI score ranges from 0 to 72; a score of 72 means that the
patient is having erythroderma. The BSA ranges from 0% to 100%,
where the percentage describes the total area of the affected skin
[34].
The costs associated with lost work productivity were calcu-
lated using the FCA [23,35,36]. Loss of productivity was then
calculated to include the time necessary to replace and train the
new employee, after which it is assumed that the original
productivity is restored. This time period (friction period) was
set to 130 working days according to the present conditions for
the Czech Republic [37,38]. The average gross wage in the Czech
Republic (€42.85/d, year 2010) was used for the valuation of lost
productivity [39]. The cost of lost productivity, using the FCA
method, is calculated as follows:
PCFCA ¼ Total loss of work productivity (based on the WPAI
score)  Average gross salary for the friction period  coefﬁcient
of elasticity. [35,40]
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into account certain corrective mechanisms (e.g., replacement of
an absent worker by a colleague) at the patient’s workplace, so
the loss of productivity is partially compensated. The level of this
coefﬁcient was 0.8.
In the absence of scores for total loss of productivity (patients
with disabilities), the score was replaced with values of 0.42, 0.60,
and 0.85 for degree of disability I, II and III, respectively. Values
are based on the current deﬁnition of the three degrees of
disability in the amendment to the Pension Insurance Act No.
306/2008 Coll. § 39 applicable from January 1, 2010.
Statistical Methods
Sociodemographic data, clinical characteristics, individual WPAI
scores, and productivity costs are presented using descriptive
statistics. Because data were not normally distributed, we have
used the nonparametric Wilcoxon two-sample test for the compar-
isons of two groups of patients and the nonparametric Kruskal-
Wallis test when more than two groups of patients were compared.
Subsequently, multiple comparisons of pairs was used to
identify paired groups of patients with statistically signiﬁcant
differences in values. Dependence of two categorical variables
was tested using the chi-square tests in a pivot table. The
relationship between a dependent variable and a set of predictors
was identiﬁed by using a linear multiple regression model. The
power of the interdependence between the two variables was
determined using the Spearman’s correlation coefﬁcient. Statis-
tical analysis was performed in program R, version 2.15.1 (R
Foundation for Statistical Computing, Vienna, Austria).T
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Patient Characteristics
From a cohort of 400 patients, 77 patients (64.9% women) suffered
from RA, 230 patients (41.7% women) suffered from AS, and 93
patients (31.1% women) suffered from psoriasis, with 23 patients
having psoriatic arthritis simultaneously. The mean patient age
was 47.1  9.5 years (range 22–62). The duration of disease was,
on average, 15.7 years; patients with RA had substantially shorter
disease durations than did patients with AS and psoriasis
(psoriatic arthritis). The lowest number of actively working (full-
time or part-time job) patients was those with AS (only 67%). It
should be noted, however, that the AS patient group was also the
oldest among all diagnostic groups, with a mean age of 49 years.
Those with psoriasis had the highest percentage of active work-
ers (95.7%).
Disease activity in patients with RA was rather high, with a
mean DAS28 of 5.6 with functional impairment, described by the
HAQ score, averaging 1.22 in patients with RA. We also found
high disease activity among patients with AS, with a mean
BASDAI score of 4.43 out of 10. Disease activity in patients with
AS, also measured using the HAQ score, had a mean value of 1.0.
It is necessary to mention that this tool was not speciﬁc to AS and
provided rather less information about the state of patients with
AS. With respect to BSA (21.1%) and PASI (12.9) levels in patients
with psoriasis, it should also be noted that patients with psoriasis
also had active and severe forms of the disease, which is by
deﬁnition an overlap of 10% in BSA and 10 in PASI, respectively.
For further patient characteristics, see Table 1.
Loss of Productivity
No statistically signiﬁcant differences were observed in absentee-
ism (Po 0.108), presenteeism (Po 0.109), overall work impairment
(P o 0.657), or activity impairment among all diagnosis. Patients
Fig. 1 – Work productivity and activity impairment (WPAI) domains.
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often compared with patients with the other diagnoses; absentee-
ism was 14.9% and 20.3%, respectively. In other words, patients
with psoriasis were absent from work on average 6 hours per week
and patients with psoriatic arthritis missed one entire workday per
week (i.e., 8 hours). Patients with RA and AS missed approximately
4 hours per week; absenteeism was 8.4% and 10.8%, respectively.
All groups of patients in our study had impaired work
performance. Presenteeism was 40.3% in the group of patients
with RA, whereas it was lower, 33.0% and 34.4%, for patients with
AS and psoriasis, respectively. The highest presenteeism was in
those with psoriatic arthritis, with a mean value of 54.2%. In
other words, patients with RA worked with reduced performance
due to illness for approximately 2 d/wk. Patients with AS and
psoriasis worked with reduced performance for shorter time
periods than did those with RA, for example, 1.7 d/wk. Perform-
ance impairment was greatest among patients with psoriatic
arthritis, who spent 2.5 d/wk working at reduced levels.
After combining absenteeism and presenteeism into one
number, the total loss of productivity was expressed. Patients
with AS, RA, and psoriasis (psoriatic arthritis) reported overall
work productivity losses of 40.9%, 42.9%, and 42.8% (60.0%),
respectively. According to these ﬁgures, we can conclude that
patients with rheumatic disease lost more than 2 d/wk of
productivity because of illness. Their activity impairment was
approximately 50.0%; however, for patients with psoriatic arthri-
tis, it was more than 70%. See Fig. 1 for the results of all WPAI
domains in all diagnoses concerned.
Functional status (HAQ) was a statistically signiﬁcant predictor
of overall loss of productivity. Deterioration of functional status, as
described by the HAQ score in patients with RA and AS, yielded
higher overall loss of productivity. Patients with AS and RA and
reduced functional status (HAQ score 42.1) had 75.5% and 52.3%
greater productivity losses compared with patients with a rela-
tively preserved function status (HAQ score o0.6). Another major
predictor of productivity loss was disease activity. For patients
with AS and RA, the more active the disease, the greater the loss of
productivity. Patients who have highly active disease lost at least
one fourth of their work time because of work impairment.
Different trends were observed among patients with psoriasis
(psoriatic arthritis), in whom greater overall work productivity
impairment was observed in those with better PASI scores and
BSA than in worse compensated patients, which can be explained
in the following way. In general, patients with psoriasis had
longstanding disease, in which progression of disease without
any intervention is common; therefore, controlling the disease
requires time-consuming treatment and care (phototherapy, etc.),
which signiﬁcantly interferes with productivity. However, this canalso be just the speciﬁcity of the cohort surveyed because there are
several studies describing the PASI score as the relevant predictor
of direct and productivity costs in patients with psoriasis (psoriatic
arthritis) [41–43]. See Table 2 for the results of subgroup analysis
according to functional and disease activity relative to overall
productivity impairment.
Productivity Costs
Total mean annual productivity costs per patient with RA, AS,
and psoriasis (psoriatic arthritis) were €1913, €1809, and €1908
(€2673), respectively (Table 3). When we translate these ﬁgures
into population levels, we can, for example, calculate the pro-
ductivity costs of all patients with AS (in the productive age 18–65
years) in the Czech Republic (8300 patients [4]) to be approx-
imately €14.8 million per year. This number represents the
maximum possible PC (or loss of productivity) because not all
patients with AS would be in such a highly active disease state as
was the case in our patient cohorts.
Regression Analysis and Correlation
By application of a multiple linear regression model, we identiﬁed
the main predictors of overall productivity loss for each diag-
nostic group. The functional status of the patient is a statistically
signiﬁcant factor (P o 0.001) that affects productivity loss in
patients with RA. We calculated that if the functional status of
patients with RA gets worse, that is, the HAQ score increases by
0.22 (minimum clinically important difference), the productivity
loss would increase by 5.3%. However, other variables used in the
model affected the loss of productivity in patients with RA just
numerically without statistical signiﬁcance. Instruments such as
the HAQ and the BASDAI can be considered signiﬁcant predictors
of productivity loss in patients with AS. In cases with increased
disease activity, that is, the BASDAI score increases by one unit,
loss of productivity would increase by 6.2% in patients with AS.
No statistically signiﬁcant predictors were found using multiple
linear regression models for patients with psoriasis (psoriatic
arthritis). Overall, work productivity impairment was strongly
correlated with patient-reported outcomes (HAQ and BASDAI),
whereas correlations with clinical parameters were rather weak.
See Table 4 for correlation analysis results.Conclusions
This study described the impact of RA, AS, psoriasis, and psoriatic
arthritis on the work productivity of patients with active diseases.
The study also compared the impact of these diseases relative to
Table 2 – The loss of productivity by functional and clinical parameters.
WPAI, RA HAQ
o0;0.64 (0.6;1.14 (1.1;1.64 (1.6;2.14 (2.1;3.04 p-value
30.1% 34.6% 55.2% 50.7% 82.7% 0.001*
DAS28
o0;2.64 (2.6;3.24 (3.2;5.14 (5.1;104 p-value
NA NA 41.6% 43.2% 0.202
WPAI, AS HAQ
o0;0.64 (0.6;1.14 (1.1;1.64 (1.6;2.14 (2.1;3.04 p-value
24.5% 40.0% 55.7% 73.3% 100,00% o 0.001†
BASDAI
o0;44 (4;104 p-value
26.5% 57.6% o0.001
WPAI, Ps (PsA) PASI
o0;54 (5;104 (10;724 p-value
63.4% (70.2%) 37.0% (62.4%) 43.4% (57.7%) 0.120 (0.841)
BSA (%)
o0;54 (5;104 (10;72/1004 p-value
68.1% (97.9%) 29.7% (49.5%) 43.6% (56.5%) 0.006‡ (0.155)
AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BSA, body surface area; DAS28, Disease Activity Score
in 28 joints; HAQ, Health Assessment Questionnaire; PsA, psoriatic arthritis; PASI, Psoriasis Area and Severity Index; Ps, psoriasis; RA,
rheumatoid arthritis; WPAI, Work Productivity and Activity Impairment.
* HAQ, RA: o0;0.64 vs. (2.1;3.04.(0.6;1.14 vs. (2.1;3.04.
† HAQ, AS: o0;0.64 vs. (0.6;1.14.o0;0.64 vs. (1.1;1.64.o0;0.64 vs. (1.6;2.14.o0;0.64 vs. (2.1;3.04.(0.6;1.14 vs. (1.1;1.64.(0.6;1.14 vs.
(1.6;2.14.
‡ BSA, PS: o0%;5%4 vs. (5%;10%4.
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the productivity loss to society in the Czech Republic, were
calculated. The effect of factors such as patient functional status
and disease activity on work productivity was observed. A statisti-
cally signiﬁcant effect, relative to loss of productivity, was described
by using multiple linear regression models and the power of mutual
dependence was described by correlations. The data about produc-
tivity losses are in general considered as rather low transferable
among various countries and governmental settings [44]. Hence, we
ﬁnd this study relevant and potentially interesting because in the
Central and Eastern Europe region, there are very limited ﬁgures
describing productivity losses and their derived costs.
Limitations of this comparison are related to the heterogene-
ity of patients with different diagnoses with respect to the
duration of disease. All comparisons of patients with different
diagnoses, however, are always questionable with regard to the
heterogeneity of the diagnoses themselves. Another limitation of
the study could be the absence of a control group. For example,
the article by Braakman-Jansen et al. [45] described the work
impairment due to RA in patients with RA; however, a work
impairment was also described within the control group without
the disease [45]. Moreover, some compensation mechanisms for
lost productivity have been described, which means that the lost
productivity of an individual does not have to necessarily mean
the same loss to society because individual productivity loss can
be compensated by other individuals. Hence, the directly meas-
ured productivity impairment of individuals (and its derived
costs) should be interpreted with caution [46].Table 3 – Productivity costs.
FCA (€) Mean  SD
RA 1912.7  1077.0 1
AS 1808.6  1261.8 1
Ps (PsA) 1908.1  1377.5 (2672.9  1243.7) 1
AS, ankylosing spondylitis; FCA, friction cost approach; Ps, psoriasis; PsAWe found that the loss of productivity is similar for all the three
diagnoses but the highest loss of productivity and related costs
were recorded in patients with psoriatic arthritis. This phenomenon
can be explained by the presence of two diagnoses within a single
patient (psoriasis as well as psoriatic arthritis). However, it could
also be a characteristic of the group surveyed. Because the number
of patients with psoriatic arthritis was low, the ﬁnal conclusion for
psoriatic arthritis burden should be stated with caution. Moreover,
other studies describing the burden of rheumatic diseases had not
reported a signiﬁcant difference in productivity loss (costs) among
the diagnoses of AR, AS, and psoriatic arthritis [13,47].
HAQ scores and the BASDAI in contrast to the DAS28, BSA,
and PASI score were signiﬁcantly more predictive of the overall
productivity loss, and therefore the costs related to it. The results
of our study are consistent with previously reported ﬁndings
[8,29,48]. A limitations of our analysis may be the fact that the
operability of the AS population was not evaluated using the
BASFI questionnaire.
The average annual cost per patient was calculated to be
approximately €2000. The study also reveals the importance of
collecting patient-reported outcomes and not dealing strictly with
clinical parameters that appear to be less signiﬁcant in relation to
the quality of life of patients and their productivity. Currently, the
health care system and treatment ﬁnancing in the Czech Republic
only considers the direct costs of health care. All costs or losses in
connection with the disease, however, should be addressed
comprehensively, not just through the myopic eye of health
care costs.Median Min Max
782.4 0.0 4456.0
782.4 0.0 4456.0
782.4 (2958.8) 0.0 (222.8) 4456.0 (4456.0)
, psoriatic arthritis; RA, rheumatoid arthritis.
Table 4 – Spearman’s correlation coefﬁcient between overall work productivity loss or productivity cost (FCA).
Correlation between overall WPAI/PCFCA and
parameter
RA AS Ps (PsA)
rS P rS P rS P
HAQRA,AS, BSA (%)Ps(PsA) 0.504 o0.001 0.618 o0.001 0.052
(0.317)
0.630
(0.185)
DAS 28RA, BASDAIAS, PASIPs(PsA) 0.099 0.465 0.665 o0.001 0.013
(0.212)
0.906
(0.385)
Note. RA: rs (0–0.19 weak correlation, 0.20–0.38 moderate correlation, 0.39–1 strong correlation); AS: rs (0–0.11 weak correlation, 0.12–0.22
moderate correlation, 0.23–1 strong correlation); Ps: rs (0–0.17 weak correlation, 0.18–0.34 moderate correlation, 0.35–1 strong correlation); PsA:
rs (0–0.34 weak correlation, 0.35–0.69 moderate correlation, 0.70–1 strong correlation).
AS, ankylosing spondylitis; BSA, body surface area; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; DAS 28, Disease Activity Score
in 28 joints; FCA, friction cost approach; HAQ, Health Assessment Questionnaire; PASI, Psoriasis Area and Severity Index; PRO, patient-
reported outcome; Ps, psoriasis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; rs, Spearman correlation coefﬁcient.
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reported outcomes and functionality of patients could also then
preserve the productivity of patients with a particular health
problem. Therefore, these interventions save indirect/productiv-
ity costs, which is the issue of biologic disease-modifying anti-
rheumatic drugs that have proved their ability of productivity
preservation in various rheumatic diseases and psoriasis [49,50].
Because of the relatively high acquisition cost of biologic disease-
modifying antirheumatic drugs, even the inclusion of the pro-
ductivity cost in the relevant costs (from the societal perspective)
may not have led to the cost-effectiveness of biologic disease-
modifying antirheumatic drugs intervention [3,51].
If a particular health care system (i.e., the Czech Republic)
opts to use other costs (the loss of productivity) and other
outcomes (employability) in the reimbursement decision-
making process, it is important to start by adequately describing
the burden of each particular health care problem with respect to
productivity under Czech conditions, because productivity loss
calculations are country-speciﬁc, and with limited transferability
[44]. This approach would be able to clearly describe the appro-
priate and comprehensive effect of treatment and intervention.
The ﬁrst step toward this goal should be active data collection on
quality of life, functional disability, and effect on productivity.
Source of ﬁnancial support: This work was supported by the
Ministry of Health of Czech Republic (grant no. 000 000 23728) and
the Charles University in Prague, Czech Republic (grant no. SVV
265 066).
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